Join today and be a part of the fastest growing B2B Network Join Now

6q Probe (6q22)

  • Origin: China
  • Supply Type: oem service

Supplier Info.

  • Company Name Wuhan Healthcare Biotechnology co.,Ltd
  • Membership:Free
  • Business Type: Manufacturer, Trading Company, Buying Office, Agent, Distributor/Wholesaler, Government ministry/Bureau/Commission, Association, Business Service (Transportation, finance, travel, Ads, etc), Other
  • Employees Total
  • Annual Revenue

ROS1 Gene Break Apart Rearrangement Detection ProbeProduct Advantages: ?1.Fleetness: Tissue probe hybridization time: 2 hours. probe hybridization time: 1 hour.?2.Accuracy: Less non-specific background staining (dyeing). Increase difficult samples detection rate.?3.Reproducibility: Different laboratories test results are highly reproducible.??About ROS1The c-ros sarcoma tumor receptor-tyrosine kinase (ROS proto-oncogene 1, receptor tyrosine kinase, ROS1) is located on chromosome 6q21 and encodes a type of portable tyrosine kinase (RTK), which is involved in the growth, proliferation, differentiation and survival of . When the rearrangement of ROS1 gene occurs, the extralar region is lost and the transmembrane and intralar tyrosine kinase regions are retained. The rearrangement sites mainly occur in the 32~36 exons of the ROS1 gene. In NSCLC, ROS1 gene mainly fuses with SLC34A2, CD74, EZR, SDC4, etc., and continues to activate ROS1 tyrosine kinase region and downstream ys, thereby causing the occurrence and development of tumors.?Probe DescriptionROS1 gene break-apart rearrangement probe uses orange-red dye to mark the ROS1 gene 5' end region and green dye to mark ROS1 gene 3' end region. The ROS1 gene break-apart rearrangement can detect all ROS1 gene rearrangements, avoiding the missed diagnosis caused by a single fusion gene.?Detection SignificanceROS1 gene break-apart rearrangement occurs mostly in young, non-smoking lung adenocarcinoma patients. ROS1 rearrangements are different from other mutations such as EGFR, KRAS and ALK. The positive rate of ROS1 rearrangement is about 1.5%, and ROS1 rearrangement positive adenocarcinoma is poorly differentiated. ROS1 break-apart rearrangement positive patients are sensitive to XALKORI (Crizotinib) drugs.Size SpecificationsReferencesRimkunas VM, et al. (2012) Clin Cancer Res 18: 4449-57.Suehara Y, et al. (2012) Clin Cancer Res 18: 6599-608.Takeuchi K, et al. (2012) Nat Med 18: 378-81.

Premium Services
Need Buyers
Girl Right
Cross Popup
Arrow 2

I Am :

Signup today to claim your Discount. Get Started before it's too late!

Arrow 1
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Ok